TOVX
Theriva Biologics Inc
$
0.438
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.4489
Open
0.4297
VWAP
0.43
Vol
342.87K
Mkt Cap
4.20M
Low
0.414
Amount
145.80K
EV/EBITDA(TTM)
--
Total Shares
17.28M
EV
-6.30M
EV/OCF(TTM)
--
P/S(TTM)
--
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Show More
2 Analyst Rating
1498.90% Upside
Wall Street analysts forecast TOVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOVX is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
1498.90% Upside
Current: 0.438
Low
7.00
Averages
7.00
High
7.00
1498.90% Upside
Current: 0.438
Low
7.00
Averages
7.00
High
7.00
Maxim
Buy
to
Hold
downgrade
2025-05-08
Reason
Maxim
Price Target
2025-05-08
downgrade
Buy
to
Hold
Reason
Maxim downgraded Theriva Biologics to Hold from Buy.
Maxim
Maxim
Buy
to
Hold
downgrade
2025-05-08
Reason
Maxim
Maxim
Price Target
2025-05-08
downgrade
Buy
to
Hold
Reason
Maxim downgraded Theriva Biologics to Hold from Buy with no price target. The firm cites the company having announced top-line data from the Phase 2b VIRAGE study evaluating oncolytic virus candidate VCN-01 in combination with chemotherapy vs. chemotherapy alone in 1st line pancreatic cancer, noting that while the key measure of median overall survival demonstrated a 2.2 month improvement and a p value of 0.0546 was just over the threshold for statistical significance, in pancreatic cancer, the mOS is key and came in narrower than expected based on the prior data. Maxim calls the overall data "mixed and unimpressive".
Maxim Group
Jason McCarthy
Strong Buy
Maintains
$25 → $6
2024-11-13
Reason
Maxim Group
Jason McCarthy
Price Target
$25 → $6
2024-11-13
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Theriva Biologics Inc (TOVX.A) is -0.08, compared to its 5-year average forward P/E of -1.24. For a more detailed relative valuation and DCF analysis to assess Theriva Biologics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.24
Current PE
-0.08
Overvalued PE
0.09
Undervalued PE
-2.57
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.02
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.15
Undervalued EV/EBITDA
-0.11
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q2
YoY :
+197.10%
-13.13M
Operating Profit
FY2025Q2
YoY :
+57.02%
-13.06M
Net Income after Tax
FY2025Q2
YoY :
-82.00%
-1.93
EPS - Diluted
FY2025Q2
YoY :
+36.92%
-4.73M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TOVX News & Events
Events Timeline
2025-08-11 (ET)
2025-08-11
08:06:33
Theriva Biologics sees cash runway into 1Q26
2025-08-11
08:05:55
Theriva Biologics reports Q2 EPS ($1.93) vs. ($10.72) last year
2025-05-27 (ET)
2025-05-27
08:16:03
Theriva Biologics announces presentation of data from VCN-01 Phase 1 trial
Sign Up For More Events
Sign Up For More Events
News
9.0
05-27NewsfilterTheriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer
9.5
05-14NewsfilterTheriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results
8.5
05-08NewsfilterTheriva Biologics Announces Closing of $7.5 Million Public Offering
Sign Up For More News
People Also Watch
FAQ
What is Theriva Biologics Inc (TOVX) stock price today?
The current price of TOVX is 0.4378 USD — it has increased 1.86 % in the last trading day.
What is Theriva Biologics Inc (TOVX)'s business?
What is the price predicton of TOVX Stock?
What is Theriva Biologics Inc (TOVX)'s revenue for the last quarter?
What is Theriva Biologics Inc (TOVX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Theriva Biologics Inc (TOVX)'s fundamentals?
How many employees does Theriva Biologics Inc (TOVX). have?